Philip Morris International Inc. (PM) Earnings Call Transcript & Summary
July 23, 2024
Earnings Call Speaker Segments
James Bushnell
executiveGood day, and thanks for being here. We put out a press release earlier today with full details about how we performed in the second quarter of 2024. You can find that release on our site, pmi.com. Exhibit 99.2 of the company's Form 8-K, which is dated July 23, 2024, along with our Investor Relations website, has a glossary of terms — the definition of smoke-free products is in there — plus adjustments, other calculations, and reconciliations to the most directly comparable U.S. GAAP measures for the non-GAAP financial measures we cite in this presentation. Remarks we're making today include forward-looking statements and projections of future results. Please turn your attention to the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that could cause actual results to differ materially from projections or forward-looking statements. Now it's my pleasure to bring in Emmanuel Babeau, our Chief Financial Officer. Emmanuel, the floor is yours.
Emmanuel Babeau
executiveThanks, James, and good morning to all of you. In the second quarter of 2024, our business turned in yet another excellent set of results. Strength in our categories was broad, producing a record first half for organic top line growth as well as organic operating income growth, if you set aside 2021, the year of pandemic recovery. IQOS kept up its powerful underlying momentum in Q2, as shipment growth and adjusted in-market sales volume growth came in above or in line with what we had expected. That mirrors one more quarter of solid advances in Japan along with healthy fundamentals in Europe, even with the ups and downs caused by the characterizing flavor ban. IQOS is bringing in more and more profit for PMI, driven by the prices we charge, the gains we get from making things efficiently, and the advantages of our size — and that's powering excellent growth. ZYN kept right on its outstanding trajectory: second-quarter volumes in the United States climbed past a 50% increase, and that's even with the supply strains we saw lately and the higher prices we've put in place. In addition to IQOS and ZYN in America, I'm pleased to say we're seeing momentum pick up in a number of other categories. It's still early, of course, but VEEV already holds the top spot among closed pods in five European markets, and it's clearly headed toward becoming profitable, while nicotine pouch volumes outside the U.S. rose above 60% during the first half, which is on par with how fast the U.S. is growing. The expansion of our smoke-free lineup shows up in a consumer base that's growing quickly — roughly 36.5 million adult users were estimated as of June 30 — and those products can now be found in 90 markets around the globe. Our combustible segment likewise beat expectations, getting back to gross margin growth sooner than we'd planned following two years of heavy inflationary pressure. Stable first-half volumes and category share, combined with cost efficiencies, drove that result, even with strong pricing. This wide-ranging performance produced organic operating income growth in the double digits alongside considerable margin expansion. As we've said before, achieving strong growth in dollar terms remains a top priority, and we're acting proactively on both pricing and cost efficiency to offset currency headwinds. You can see this plainly from our first-half adjusted diluted EPS, which grew at a mid-single-digit rate even though currency created a headwind exceeding 12%, since nearly the entire anticipated effect for the full year landed in the first six months. After such a standout first half, we're raising our 2024 full-year guidance across every organic measure, and for adjusted diluted EPS both in currency-neutral terms and in U.S. dollars. That mirrors our robust second-half outlook, with IQOS adjusted IMS growth picking up speed, ZYN volumes rising from one quarter to the next, and the pace of USD EPS expansion increasing at current exchange rates. Turning to the key numbers on the top line: our total shipment volume expanded a solid 2.8%, and that pushed Q2 organic net revenue up 9.6%, which works out to 5.6% when measured in dollars. With that healthy sales increase, a favorable mix toward smoke-free products, and continued savings on costs, we were able to post adjusted diluted EPS of $1.59. That marks a gain of 10.6%, once you set aside an unfavorable currency swing that came in bigger than we had anticipated at $0.18 — and that figure includes a modest transactional effect tied to exchange-rate movement late in the quarter. This result, which beat our expectations on an ex-currency basis, speaks to strengthening profitability across IQOS, ZYN and combustibles, and I'll return to that point shortly. Turning to the first half as a whole, shipment volumes increased 3.2%, while organic net revenue rose 10.2% — the strongest expansion we've posted since the 2008 spin. Solid results in both smoke-free and combustible lifted operating income 17%, as organic margin widened 230 basis points and dollar-term growth reached 7.1%. For the second half, we anticipate ongoing, healthy OI gains on a reported basis and organically alike. H1 adjusted diluted EPS climbed a notable 16.8% at constant currency, and 4% in dollar terms. Within the $0.38 H1 currency headwind, $0.08 stems from nonrecurring transactional effects tied to Egypt and Russia. Now on volume: total shipment gains for the quarter and for H1 combined mirror smoke-free share capture within a resilient global industry that expanded over 1% in each period, even with oral and e-vapor left out. Q2 HTU shipments reached 35.5 billion units, above our earlier guidance, fueled largely by sustained strength in Japan, solid underlying momentum across Europe, and encouraging expansion in newer markets like Indonesia. Beyond that underlying momentum, Q2 carried an incremental phasing effect of roughly 0.5 billion units, mostly linked to Red Sea disruption. Adjusted IMS volume in Q2 rose 10.2%, matching what we expected. That figure reflects the characterizing flavor ban in Europe, especially in Italy during the quarter. In the second quarter, our total smoke-free adjusted in-market sales volume increased 11.2%, and for the first half it was up 13.1%. This figure covers our oral smoke-free portfolio, which is driven by ZYN, and in Q2 pouch shipment volumes rose 20%. U.S. ZYN shipments increased 50%, hitting 135.1 million million can. What isn't reflected here are the promising results from our e-vapor business, where year-to-date volume grew significantly, reaching the equivalent of 0.7 billion units. Cigarette shipments rose 0.4%, with notable support from Turkey and North Africa. This occurred even with step-up pricing and indicates a stable category share once market mix is excluded. With that robust first-half shipment performance in hand, we now expect total unit volumes across cigarettes, HTUs and oral products for the entire year to land between 1% and 2% — a range that would mark a fourth consecutive annual gain in volume. The slide makes plain how powerful our multi-category smoke-free shift has become, working in tandem with the combustible rebound, because each contributed heavily to the 12.5% organic operating income increase the group posted for Q2 — a double-digit result. Momentum in smoke-free stayed exceptional, with organic net revenue up 18% and gross profit up 22%, and those figures produced 220 basis points of organic gross margin expansion. That performance reflects ZYN's impressive results together with the scale and efficiency advantages coming from IQOS, among them manufacturing productivities, plus a contribution from VEEV that keeps growing even though it remains on the smaller side. The favorable mix impact from our transformation keeps getting stronger, since smoke-free gross margin is widening its lead over the combustible side by an ever-greater amount. Still, one of our main goals remains lifting combustible gross margin. After seven straight quarters of decreases, we're happy to report growth of 50 basis points, plus organic gross profit up 5.5%, giving total PMI profitability a meaningful lift. That reflects volumes holding up even with extremely strong pricing, as well as ongoing efficiencies and reduced pressure on our COGS, despite tobacco leaf inflation that continues. For H2, we likewise expect combustible gross margin to expand. Combined with an exceptionally strong first quarter, the year-to-date position looks even more competitive, delivering double-digit growth in organic net revenue, gross profit and OI. We saw the same trend in Q2, with gross margin up a strong 390 basis points and gross profit for our smoke-free business rising 29%. For H1, our revenue results again show what powers our financial model: a one-of-a-kind blend of volume gains, strong pricing, and a highly beneficial category mix from our smoke-free products. As we mentioned, volumes rose 3.2%. Pricing contributed 6 points of growth, which includes 8.3% pricing on combustible and roughly 2% on smoke-free. Mix within the smoke-free category added 2.5 points to the top line, driven by higher net revenue per unit for IQOS and ZYN.
Emmanuel Babeau
executiveEven though it's still modest in size, VEEV made a favorable contribution to the total blend as well. I should add that oral smoke-free offerings chipped in 2 points to organic net revenue growth, which highlights the ongoing benefit we're seeing from bringing Swedish Match into the fold. Geographic mix worked against us, just as it did in prior quarters. The main reason is combustibles, where rising volumes come from lower-margin markets where smoke-free options are limited or unavailable, while higher-margin markets are disproportionately affected by cannibalization. We anticipate this effect will carry less weight in 2024 compared with last year; let's now turn to how our H1 margin was achieved. Gross margin rose 140 basis points on an organic basis and 80 basis points in dollar terms; the improvement came from our smoke-free business with its higher margins, from pricing, and from continuous productivity gains throughout the value chain. SG&A cost growth picked up in Q2 as anticipated, rising 9.8% organically following only a slight bump in Q1 tied to the planned timing of commercial spending. The 5.8% organic rise for H1 that resulted stayed under the pace of top line growth, producing plus 1 percentage point of margin expansion, while our effective back-office cost initiative offset part of the investment increase. Given the many important commercial initiatives in Q3, we anticipate SG&A will stay elevated, yet we still aim for an organic rise under the rate of net revenue growth for the full year. I'm happy to share that we achieved more than $300 million in H1 gross cost efficiency spanning both COGS and SG&A as we actively pursue bottom line growth. We anticipate savings will speed up in H2, particularly from manufacturing, as we move toward our $2 billion goal for the '24-'26 period. Together, these elements produced a plus 230 basis point widening of our organic operating income margin. Even with a sizable currency headwind concentrated in H1, adjusted OI margins held steady in dollar terms. Turning to our smoke-free business. We estimate 36.5 million adult users of PMI smoke-free product were present as of June 30, which means an extra 3.2 million joined during H1. That figure includes an estimated 30.8 million IQOS users, 5.2 million oral users and 0.8 million VEEV users. Growth in total users and in IQOS users alike was broad-based, with strong gains in Japan, Europe and newer growth markets like Indonesia, alongside robust uptake among legal age nicotine users in the U.S. Our smoke-free products now reach 90 markets, after the recent introductions of IQOS ZYN and VEEV. Let's focus now on IQOS in Europe, where the underlying trends are shaping up quite favorably, including the user growth I mentioned earlier. First, we're seeing solid rebounds in markets where the characterizing flavor ban has moved past its initial adjustment period. Second, growth remains excellent in markets where IQOS is already firmly established, including Portugal, Hungary and Greece. Finally, new growth leader markets are surfacing with quickening momentum in Germany, Spain, Bulgaria and Romania, along with a rebound in Poland after DELIA's launch. During Q2, our HTU share rose 0.8 points compared to the same period last year, even with the flavor ban weighing on results. Because of typical seasonal patterns and a sturdy combustible category, our Q2 share came in lower than Q1 on a sequential basis. On the 4-quarter moving average, adjusted IMS volume for HTU showed strong expansion, climbing 0.8 billion units quarter over quarter to hit 12.9 billion. As we had expected, adjusted in-market sales growth of 6.8% fell short of Q1, reflecting a tougher comparison and the early effects of the characterizing flavor prohibition, particularly in Italy. Outside of Italy, growth approached 10%. In most markets, the ban's effect is unfolding consistent with what we previously projected, although implementation in Italy during Q2 proved somewhat stronger than we had foreseen; this largely stemmed from quicker sell-through of impacted SKUs alongside pricing actions taken at the same time. It's worth emphasizing that this is a temporary situation, and I'm happy to say we're seeing recovery in markets like Greece, Czech Republic, Bulgaria and Romania, where the ban had already been put in place earlier, following a first phase of consumer readjustment. In fact, notwithstanding an unpredictable situation in Ukraine, we expect Europe's adjusted IMS growth to speed up during the latter half of the year. This is underpinned by our planned increase in commercial efforts supporting IQOS, which includes bringing DELIA and LEVIA HTUs into a growing set of markets. A further sign of our ongoing momentum in Europe can be seen in our key city offtake share. Significant advances in cities where IQOS adoption is already elevated, such as Budapest, Bucharest, Bratislava, Lisbon and Sofia, along with markets that historically grew more slowly, such as Madrid, London and Amsterdam, underscore the region's lasting capacity for growth. Japan posted remarkable IQOS growth this quarter, with adjusted HTU IMS growth of 12.5%, marking the seventh quarter in a row of double-digit gains. Adjusted IMS volumes kept rising sequentially, hitting 10.5 billion units on a 4-quarter moving average. Total tobacco share for our HTU brands climbed 3.1 points versus a year ago, reaching 29.4%, while national offtake share surpassed the notable 30% threshold in June. We also held offtake share above 35% in Tokyo despite seasonal influences, where the total category kept running at more than 50% of overall offtake and expanded sequentially, showing the ongoing opportunity in this vital market. Ongoing innovation remains a major force behind this growth, and Q2 brought a significant boost in user acquisition after the debut of ILUMA i and additional novel cigarette variants like capsule consumables. Looking more broadly across the globe, we keep witnessing highly encouraging IQOS growth throughout a wide array of geographies, among them low and middle income markets, as reflected in key city offtake shares. The fastest momentum comes from Indonesia, the biggest cigarette market worldwide by volume when China is excluded, driven by broader geographic coverage and clove HTU innovation. Markets throughout North Africa and the Middle East are likewise gaining share and contributing to growth. Here we list Saudi Arabia, Lebanon, Morocco, and Tunisia, plus Egypt, where Cairo's results are still solid even with the pricing moves lately and a rebound in the combustible segment. I'm glad to share that the UAE and Jordan are making excellent strides too. After ILUMA's recent introduction, Mexico City's momentum looks highly encouraging. South Korea and Malaysia, our East Asian markets, are also holding up nicely. Another point worth noting is how well Duty Free is contributing, since we're leaning more and more on our multi-category range to gain share in an expanding market while travel in Asia bounces back. Our basic HTU growth projection for this year remains the same. A plus 11.4% rise in H1 adjusted IMS growth captures the robust momentum I outlined for Japan, Europe, and global markets, though the temporary effect of the EU flavor ban offsets part of it. In fact, growth outside Europe sped up relative to last year, and we anticipate that pattern will persist. That said, we now foresee an added headwind of roughly 2 billion units against our full year adjusted IMS forecast, most of it stemming from the continued wait for approval to commercialize in Taiwan, which had been anticipated near the middle of the year.
Emmanuel Babeau
executiveAdditionally, we’re accounting for a hit of several hundred million units tied to a slower rebound from the characterizing flavor ban in Europe, mainly in Italy. It’s worth pointing out that our updated projection for the full year of roughly 13% adjusted IMS growth still equals the same absolute volume gain seen in 2023, even with that EU obstacle. So we’re projecting full year HTRU shipment volume near 140 billion units, and as always, shipments should come in a few billion units above adjusted IMS because of continued offtake and user growth. Crucially, we anticipate a particularly robust H2 performance in adjusted IMS, both quarter over quarter and versus the prior year, landing between plus 14% and plus 15% growth. That’s backed by a clear pickup in commercial activity, ongoing momentum in Japan, and a global market that’s becoming more dynamic; this covers the market I just referenced along with the steady acceleration in Duty Free. When it comes to Europe, wider growth from faster movement in Germany, Spain, the U.K., and Romania builds on existing momentum in places like Portugal and Greece. H2 should also bring several markets beginning to bounce back from the initial favorable effect, among them a steady improvement in Italy. Now shifting to ZYN, where solid U.S. gains carried on in Q2, at nearly plus 70% growth in 12 months rolling shipments. As we mentioned earlier this year, powerful demand trends have led to near-term supply chain limitations, which have held back volume growth. This slide shows how that produced a short-lived deceleration in the category. ZYN’s premium positioning and stronger brand equity stay intact, with ZYN holding onto very sturdy category volume and value share even with these availability issues and the latest price increase. We’re also still sharply focused on marketing ZYN responsibly to avoid unintended use. We’re making solid headway on boosting production and still anticipate steady improvement through Q3, with volume rising sequentially and production volumes matching expected consumer demand over the course of Q4. We expect the continuing enlargement of the current Kentucky facility to deliver roughly 900 million cans of capacity for 2025. We also just announced a planned investment in a new Colorado plant, which should start preliminary operation by the end of next year. Taken together, these moves back our U.S. ZYN growth goals for years ahead. For 2024, we now project a U.S. shipment range of 560 million to 580 million cans, reflecting sharply rising demand from adult nicotine users and the strides we’ve made in lifting production capacity. I’ll pause here to bring you up to date on the international growth of our smoke-free business. Our multi-category strategy is building momentum as we open a new horizon of growth through greater commercialization of IQOS, ZYN, and VEEV across markets. Our targeted approach for VEEV is delivering very encouraging early results; in Europe, closed pods are speeding up within the fast-moving e-vapor category. We're experiencing robust momentum with VEEV ONE, securing the top closed pod spot across 5 markets during its debut year, among them Italy, the Czech Republic, and Romania; repeat purchasing and conversion rates remain healthy, which tends to be difficult in this segment. We anticipate sustained volume growth in H2, driven by continued geographic rollouts, and expect to hit profitability in Q3. When it comes to ZYN, a substantial opportunity exists beyond the U.S. that we're striving to seize. Our nicotine pod volumes internationally, the Nordics included, rose by more than 60% during H1, on par with ZYN's U.S. growth; encouraging outcomes are appearing across several markets, such as Mexico, South Africa, Pakistan, and the key U.K. market, where traction has been strong despite distribution remaining limited thus far. Work on broadening the IQOS lineup stays active as we innovate to widen and improve what we offer both current users and smokers making the switch. Additional market introductions are set for H2, among them DELIA and LEVIA HTUs plus the new ILUMA i device brand, which right now is sold only in Japan; meanwhile we're continuing preparations for IQOS ILUMA in the U.S., and consumer engagement has begun for our inaugural city pilot in Austin, Texas using the IQOS 3 system, which should kick off in Q4. As noted before, commercialization will at first be narrow in scope, centered on directly activating selected legal age smokers across a handful of cities, letting us test various components of the commercial model. The core aim is refining our approach and readiness ahead of the full-scale ILUMA launch. We still expect FDA authorization during the latter half of 2025. Turning next to combustibles. Our portfolio posted solid organic net revenue growth along with a strongly favorable profit contribution, as discussed earlier; this shows volume resilience even with exceptionally strong Q2 pricing of 8.7%, including steps we took proactively to maximize growth. Notably, the vast bulk of our pricing comes from routine price increases rather than any major currency devaluation. Given a robust H1 and encouraging outlook, we now project a higher full year combustible price variance of 7% to 8%. Cigarette category share held steady in H1 and slipped 0.2 points in Q2, or was flat once market mix effects are excluded. Softer share in Egypt and Indonesia was balanced out by gains from Turkey, India, and the Europe region, once again in spite of strong pricing. Our global brands lifted category share during the quarter, with Marlboro up 0.3 points to 10.1%. Globally speaking, our combustible leadership plays an essential role in enabling maximum switching toward smoke-free products, and our goal is a stable category share across time. As stated earlier, we assess strategy market by market and retain flexibility to adjust where smoke-free products have already achieved critical mass. Adopting a broader perspective on the business. Embedding sustainability into everything we do is what supports our transformation and smoke-free journey. Our targets for transforming our product portfolio are seeing solid movement. Smoke-free offerings can now be found in 90 markets, which keeps us on the path toward our aspiration of 100 by 2025; likewise, we are advancing well on our goal for low- and middle-income countries to account for more than 50% of smoke-free product markets. The swift expansion of our estimated SFP user base, now at roughly 36.5 million adult users, as described earlier, offers additional evidence of that progress. Turning to operations, decarbonization remains a key priority, and we take great pleasure in securing the top spot on the Forbes 2024 Net Zero Leader list, which spotlights the 100 U.S. public companies best positioned to cut their greenhouse gas emission; it also comes after the announcement earlier this year that CDP gave us a AAA rating for our disclosure and efforts on climate change, forest and water security. Such recognition shows our ongoing dedication to sustainability performance and strong reporting as we keep working toward a smoke-free future. That leads me to our outlook for 2024.
Emmanuel Babeau
executiveFollowing a strong opening six months and good business momentum going into the back half, we are raising our full-year growth outlook in both currency-neutral and U.S. dollar terms. What's driving that: quicker expansion in overall volume plus pricing, a very strong ZYN outlook despite a near-term supply limitation, and better IQOS profitability thanks to operating leverage, manufacturing efficiencies and pricing; our goal for smoke-free net revenue this year stays at approximately $15 billion. Taking all of that into account, together with a robust combustible performance, we are increasing our organic net revenue growth guidance to a range of plus 7.5% to plus 9%. On top of that robust revenue increase, favorable smoke-free product composition, a rebound in combustibles, and further expense savings permit solid margin gains. Therefore, we are lifting our projection for organic operating income growth this year to between plus 11% and plus 13%; our objectives stay the same for adjusted gross margin improvement across both smoke-free offerings and combustible items, along with adjusted OI margin growth for PMI overall, each measured on an organic basis and in dollar terms. Consequently, and factoring in a reduced anticipated net financing expense, we are also boosting our outlook for currency-neutral adjusted diluted EPS growth to plus 11% to plus 13%. That comes to somewhere between $6.33 and $6.45, and for the full year, at rates as they stand now, currency works against us to the tune of $0.34. What's driving the larger currency drag versus what we told you before is mostly the Q2 effect I already walked through. Our forecast for USD EPS growth has moved up to a range of plus 5% to plus 7%, and that demonstrates how the fundamental momentum in the business, along with steps we've taken proactively to offset the pressure, has allowed us to do better than merely make up for it — so we're on track to hit our goal of solid growth measured in dollars. Now let's dig into the second half a bit more. We're anticipating yet another solid quarter, powered by very good adjusted IMS growth for IQOS, steady sequential gains in ZYN volumes, and the ongoing favorable effect of the steps we're taking to boost the bottom line. Looking at Q3, we're projecting quarterly adjusted diluted EPS at an all-time high of $1.77 to $1.82, even with a notable increase in commercial investment and a currency headwind of $0.02 based on current rates. That stands in contrast to an expected currency benefit of $0.04 across H2 as a whole, which lets us aim for faster growth in U.S. dollar adjusted diluted EPS. You'll find a table in the appendix showing our estimated currency impact by quarter. For Q3, this forecast clearly shows yet another period of strong expansion, with HTU shipments reaching 34 billion to 35 billion units, alongside faster growth in HTU adjusted IMS. Since we anticipate solid profit results for the entire year, our projection for operating cash flow sits near $11 billion — the top of the range we gave earlier, assuming current exchange rates and depending on working capital needs at year-end. We believe that gain will outweigh the rise in capital expenditure, which will land somewhere between $1.3 billion and $1.4 billion, as we push ahead more quickly on expanding ZYN capacity. Finally, for 2024 we're still aiming at a 0.3x to 0.5x gain in the ratio of net debt to adjusted EBITDA, powered by rising profits and robust cash flow creation. By June 30, we'd already brought that ratio down to 3x on a trailing 12-month basis, versus 3.2x when 2023 closed. That's solid movement toward the roughly 2x objective we've set for the close of 2026. Once that aim is nearly in reach, we plan to revisit share repurchase, pending board approval. Now I'll wrap up today's presentation with a few final thoughts. Combining potent underlying business momentum with the proactive moves we've made lets us produce best-in-class growth across key metrics. Even with ongoing foreign exchange pressures, our approach continues to produce results across shipment volumes, price realization, operating cash, and earnings in dollars. Evidence that our shift toward smoke-free products is working appeared in an exceptional first half, driven by outstanding growth in underlying IQOS and ZYN, price levels that held up remarkably well, a beneficial category mix, and greater cost savings; all of this keeps us firmly on track for a remarkable 2024, one marked by quicker revenue growth and wider margins. That momentum continues to build across every part of the company, and a compelling opportunity to grow in multiple categories will further support our ability to meet the growth objectives we've set for 2024 through 2026. Achieving results measured in dollars stays our central priority. And as the first half showed, we are taking actions to counter currency pressures. Finally, we remain fully committed to returning cash to our shareholders. Our growth prospects and powerful cash flow creation support the capital allocation priorities of reinvesting behind a business that's transforming quickly, together with our progressive dividend policy. Thanks, and we're now delighted to take your questions.
Gaurav Jain
analystSo I have a couple of questions. First, regarding that pricing algorithm for cigarettes you use. When I look at how your market share has grown, it's obviously very impressive, even if I leave out modern oral. And when I include it, you're picking up nearly 80 basis points of share each year right now; so doesn't a gain of that size seem too much and point to the idea that you aren't monetizing your cigarette business as fully as you ought to be? And wouldn't that imply raising cigarette pricing growth from 7% to 8%, or say from 8% to 10%? Then I have a follow-up.
Emmanuel Babeau
executiveThanks, Gaurav, for that question. Look, let's be clear; you can always push back on whether we might do even better when it comes to raising price. The reality is that we're performing better than what we originally expected. We've had this really strong result, an 8.7% price increase for combustible in H1. I believe we're all aware that the inflationary backdrop is not what it was a year ago. So clearly, this is a really strong result. Please keep in mind, I mentioned it in my preliminary remarks, but roughly 3/4 of that does not come from inflation in — sorry, from a price increase in a country with very high inflation. And this 8.7% in Q2 is mostly driven by the markets where we are truly pushing price in a somewhat opportunistic way, building on the strength of our portfolio and making sure we are always optimizing the potential for price increase. So you can be completely certain that this is very granular work, market by market each time as we signal, we factor in what our position is on smoke-free product in this market, what the impact of raising price is. And I think we can show that we have a very successful approach on this price increase. So I would lean toward believing that we are optimizing this price increase potential in the current environment.
Gaurav Jain
analystYou said ZYN's capacity is going to rise to 900 million cans in the coming year. Does that therefore imply that by Q4 of this year it will hit 225 million cans each quarter?
Emmanuel Babeau
executiveWell, let me confirm that our target is to reach roughly 900 million cans of production capacity for the next year, meaning the full year 2025. Bit by bit we're raising our capacity, and there are a number of steps being taken. I won't go into the details of those, but several levers are being pulled by us to lift this capacity; so I'd put it this way — each quarter compared with the one before, our capacity is getting better. A forecast of where we'll stand at the close of the year is not something I'll provide. Based on what we currently observe regarding possible consumer demand, we think that when it comes to what we make at a given point in Q4 against what consumer offtake might be with no restriction, we'll be fine. After that we'll see precisely how we end up in terms of capacity at year-end; but the thing I consider more pertinent and, honestly, more significant is that you have the picture of this 560 million to 580 million cans, which is our goal for 2024. As you're aware, we have that capacity of 900 million cans for the coming year. Let's be clear, this isn't guidance on next year's volume. What we're doing here is simply giving the capacity we're working on; and with that, I think you have what matters.
Bonnie Herzog
analystI'd like to ask about your guidance. You lifted your expectations for both top and bottom line growth, yet you trimmed your outlook for HTU shipment volume a bit; you said this was due to a somewhat larger-than-anticipated effect from the EU flavor ban; you did mention it, but I was hoping you could give a bit more detail on that, plus any other effect on HTU volume you anticipate in the back half? Do you expect IQOS growth to stay strong in Japan during the second half, for example? And last, you said your HTU guide assumes zero volumes in Taiwan. So perhaps an update on that regarding timing?
Emmanuel Babeau
executiveSure, Bonnie. I appreciate the chance to give you some additional detail on IQOS and the favorable momentum we're observing. To begin with, it's true that we're reducing our adjusted in-market sales guidance by about 2 billion. The bulk of that cut, as I mentioned, is tied to Taiwan. Basically, our expectation had been that Taiwan would come online sometime after the first six months of this year. In the end, we're now modeling no volume at all out of Taiwan. We felt that was a reasonable way to look at it. Keep in mind the legislation permitting an age of tobacco product was enacted 15 months ago, so we assumed that within that window, there would be the ability to secure the regulator's approval. Also, there's an administrative step involved—you ask questions, there's a Q&A—and it's simply consuming far more time than we had anticipated. But the main driver behind this $2 billion adjustment to adjusted IMS is Taiwan. On top of that, we've got a few hundred million coming out of Europe. So that's essentially the whole story behind the $2 billion. Because of Taiwan, we're now indicating that instead of expecting to exceed 140 billion in shipments, our current projection is roughly 140 billion. That's the right way to interpret this guidance change. That said, give me a couple of minutes to go through the dynamics, because I want everything to be completely clear. What we observed during H1 is really an acceleration of the IQOS business beyond Europe. So when you examine adjusted in-market sales outside Europe — which represents 60% of the business — adjusted IMS grew roughly 14%, compared with roughly 13% a year ago; in other words, our growth rate in percentage terms has picked up. When you think about the quantities involved, naturally, that translates into a pretty major step up in pace. And really, sitting behind that rather impressive momentum is Japan. South Korea is another developed market in the mix, but a handful of fresh sources have been fueling this expansion; Indonesia came up earlier. We also touched on a few Middle Eastern markets. Mexico is gaining momentum as well, and Duty Free is delivering solid numbers too; so that basically sums up what's happening beyond Europe; as for Europe, it's playing out exactly as we anticipated. To put it another way, a significant shift is underway; we're moving away from flavor. It continues to grow. Beyond Italy, our adjusted in-market sales are climbing at nearly double-digit rates. So there's a lot of momentum even though many countries are working through this transition. And as we noted, it's genuinely encouraging to see, simultaneously, our best-performing market, as we said in Portugal, Greece, Hungary, continuing to perform very strongly. We have fresh markets that are truly proving they are growth engines going forward. We brought up Germany, Spain, Romania, and Bulgaria. So it matters that we now have these additional growth drivers, in a manner of speaking. And then, as I'd put it, a number of markets are emerging as expected from the disruption—or the upheaval, I should say—of those several weeks connected to the flavor ban's implementation. On that point, we can name Greece, Romania, Bulgaria, and the Czech Republic. So that's a group of markets where things are playing out precisely the way we thought they would. Then you have Italy, where honestly we hadn't correctly gauged how much flavored inventory distributors and retailers were holding, and it turned out to be less than we had presumed. And as a result, consumer offtake was hit faster than we had forecast because no flavor product was available once the flavor ban took effect, and that has weighed somewhat on growth; and at the same time, there's no question that the 2 things piling up have had an effect. On consumables, we've implemented a $0.30 price increase. Competitors have only followed suit to a small extent. As usually happens when we make a significant price move and the gap with rivals grows, our market share has taken a hit, along with those competitors who did respond. That's basically where things stand. Looking ahead to the back half, we anticipate continued strong performance outside Europe. I won't go through the full list again of those outstanding markets where results are very good. LEVIA and DELIA are being introduced in multiple countries. And once we get past this adjustment period tied to the flavor ban, we expect Europe to accelerate. And Italy will be among the markets where we anticipate improvement; but broadly speaking, I'd say, we expect greater acceleration across all the markets that have gone through the flavor ban. So I believe that's truly the full picture, Bonnie. I hope it helps in answering your question.
Bonnie Herzog
analystThat was genuinely quite useful. I'm grateful that you walked us through everything. And then, if I could, I'd like to pose something about ILUMA i in Japan. I suppose I was hoping for additional detail regarding this device, which, as far as I understand, can currently only be bought in Japan. And I'm interested to know how substantial the boost has been, or basically how much incremental gain, and truly what you're observing or hearing from buyers when it comes to their embrace of the new device, the effect on your growth, margins, and so on? And last, what you intend regarding additional rollout of this device.
Emmanuel Babeau
executiveCertainly, Bonnie. You're correct. ILUMA i, the newest iteration of IQOS ILUMA. It doesn't alter the core technology, yet the device delivers several extra features, and at present it exists solely in Japan. A launch in a handful of other markets is scheduled for H2; and it's invariably hard to pinpoint what a new product like this sets off, though we have plainly observed fresh acquisition of IQOS users. We have observed consumer sentiment rising, with quite favorable feedback toward this product. So I'd put it this way: we keep having added firepower to switch smokers over to IQOS, to enhance the experience, to enhance customer satisfaction, which naturally drives greater loyalty, which may influence average daily consumption, so multiple beneficial outcomes. That's what we've witnessed in Japan. It's hard for me to state precisely how much this has further sped up growth in Japan, but it was a plus for the market.
Matt Smith
analystCould you give us a bit more granularity regarding how oral pouches are growing in markets outside the U.S.? You mentioned some early wins in a few countries. Are you still widening distribution in those places? And do any capacity limits exist for those international markets beyond the U.S.?
Emmanuel Babeau
executiveSure. It's coincidental, I guess, but it's accurate that during H1, nicotine pouch growth beyond the U.S. closely matched what happened inside the U.S. — though be careful here. We're referring to just 10% of U.S. volume. That figure is part of the total — not entirely negligible, since the Nordics are counted. What we're plainly observing is that nicotine users in numerous countries show some interest and appeal. I'd really separate 3 buckets of potential expansion for this market. First, obviously, you've got the Nordic countries, which possess the familiarity, the comprehension, and the cultural connection to this product, and where the nicotine pouch category is vibrant. There, we intend to claim our rightful portion of that growth. Next comes Europe, where the category isn't significant in every market, yet we can already point to a set of countries like Austria, the U.K., and Switzerland, where we think potential exists, and we're witnessing growth. And then there's what I'd call the global market, the international market. We can mention Pakistan, we can mention South Africa; we could bring up Indonesia and the Philippines, where we perceive potential for these nicotine pouches. You might already have some oral product culture there; and we're seeing the product develop. I might add Mexico to that list, incidentally, where we're launching the development of ZYN quite nicely. So we observe that this product — perhaps owing to U.S. influence, which is obvious in a country like the U.K. — is a category that could spread in awareness, I'd say, intriguingly and swiftly, and we absolutely want to ensure we capture our rightful portion of this opportunity.
Matt Smith
analystAnd I just have one more quick question. When it comes to that international business, are there any limits on capacity? Or is capacity there not restricted the way it is in the U.S.?
Emmanuel Babeau
executiveNo, at this point I don't have any capacity problem to report.
Faham Baig
analystHey Emmanuel, appreciate you taking this. I have two things as well. First, about the vapor segment, and second, regarding ZYN. I realize you plan to grow things with your VEEV offering, but what's your view on how the vapor segment will evolve, especially beyond the U.S.? Which kinds of users are drawn to this segment? Take Europe, for instance — I'm simply trying to figure out if those who vape regard it as a substitute for eating tobacco? Or is it that these 2 segments pull in a different set of consumers, especially after the flavor ban in Europe?
Emmanuel Babeau
executiveSure. Do you want to raise your ZYN question at this point? Or would you rather return to ZYN afterward?
Faham Baig
analystMaybe I'll jump back in afterward.
Emmanuel Babeau
executiveAll right. So when it comes to vaping, what we're observing, I believe, aligns with what we've consistently stated: vaping is a legitimate category offering an alternative for those who would otherwise smoke. That means it's a category experiencing growth — though not necessarily at a quicker pace than eat-not-burn, and definitely not quicker than nicotine pouch; naturally, nicotine pouch starts from a smaller base. We also recognize that vaping tends to be more attractive to people of legal age and above who are looking to begin using nicotine, while switching existing smokers over is considerably harder; that's precisely where IQOS and the eat-not-burn segment perform much better. So indeed, vaping may hold appeal for certain legal-age-and-above nicotine users. Converting smokers is harder, quite plainly. Following the flavor ban's implementation in Europe, we have not come across any significant report of individuals shifting to vaping, nor of any shift in the category's underlying dynamics. Naturally, we're keeping watch on that. Yet as I mentioned, there's nothing we can clearly point to regarding such a trend, which might suggest we're discussing people who likely have a different profile — but that's something we'll need to continue tracking, naturally. So we've always maintained that the worry surrounding vaping is this: if products aren't developed and marketed properly, if there's an excessive pull toward flavor, that could lead to unintended usage, and that poses a problem for the category. We're quite pleased with our growth, since we go about it very responsibly — both when it comes to developing our product and developing our marketing activity. And we're building out this responsible approach, grounded heavily in our commercial strength along with an excellent product. In my view, VEEV ONE is an excellent product, and our strong partnership with the trade is delivering this very good start, as we noted — the #1 position across 5 countries for closed pods. That's genuinely all I can share with you at this point.
Faham Baig
analystYes, that helps. Moving to the second point, ZYN in the U.S. Based on Scanner data — a portion of which came in today too — because the volume momentum has been declining quarter over quarter, even though it's only very, very low single digits, could you estimate what volumes might have been absent the capacity limitation? Also, for the back half, when you anticipate volumes accelerating, does that mean you'll start picking up market share? Or is it mostly the result of the overall category speeding up further?
Emmanuel Babeau
executiveRegarding ZYN, I believe we noted that we're clearly operating under certain restrictions. So I'm not certain that what you're seeing in Nielsen, which reflects availability, provides a read on the trend and on consumer demand; we're steadily getting better, and we expect availability to show that over the next few months. As of today, we've made clear that we're aiming for roughly 900 million can capacity next year. That gives us quite attractive room to grow over the quarters ahead. We consider that genuinely important. I can't give you a figure, because honestly there's no way to determine what the growth rate would have been without the constraint. Keep in mind that certain rivals made pricing moves last year, which set off a jump in our market share, and that impact has now passed; so it's also affecting the year-over-year comparison; that's all we can offer on ZYN.
Faham Baig
analystLet me just fit in one final question if possible. Has anything changed regarding the assessment of ZYN sales following that subpoena in the District of Columbia, which is still in progress and led you to shut down zyn.com sales — and when could that bounce back?
Emmanuel Babeau
executiveRight, I'm aware, no fresh developments exist. We continue our work and, naturally, are cooperating completely with the Attorney General. At this point, it's not possible to predict how many days or months this effort will require, nor what the outcome will be. And as of today, nothing has changed.
Owen Bennett
analystTrust you're doing okay. I've got two things about how pouches are behaving in the U.S. To start — my guess is this stems from some retailers attempting to cover the shortage. In a number of shops, I've noticed Scandinavian ZYN on the shelves. So I'd like to know what steps you can take to stay ahead of that and guarantee it isn't occurring; and then next, I'm also seeing brands beyond oral ones showing up now, which I presume lack a PMTA submission. So in your view, what's the danger that a comparable situation emerges with pouches here in the U.S. to what we're observing with legal products in vape?
Emmanuel Babeau
executiveSo what you're referring to is product that would originate outside the U.S. market, is that right? That's what...
Owen Bennett
analystWhen it comes to retail, distributors are purchasing those products over the internet from Scandinavia, attempting to cover the shortage in supply. I'm just curious how you might address that, to ensure it isn't occurring?
Emmanuel Babeau
executiveWell, I have no knowledge regarding that matter. Therefore I'm unable to offer any remark or account. I believe that in every location, we're making the greatest possible effort to guarantee that shipments are suitable and aren't heading to places where they ought not to go. And we're striving extremely hard toward this aim. And I possess no figures, and I can't respond to that. Yet our stance is quite plain. We take a very firm approach, doing all within our power to guarantee that such unauthorized channels aren't taking place; regarding your inquiry on — if I'm understanding you correctly, at what point might — are we observing a similar type of occurrence with nicotine pouch as the one we're witnessing with vaping, meaning illegal parallel distribution that would be coming into the U.S. market?
Owen Bennett
analystYeah. I'm beginning to notice brands that, as far as I can tell, don't carry the MTF. I'm just curious — how do you assess the risk there?
Emmanuel Babeau
executiveAs things stand, based on what we're able to track in the marketplace, nothing strikes us as material at this point. That said, we're certainly keeping a very close watch on it. Should it ever turn material, my sense is that what's plainly evident right now is that regulators treat this seriously, and they're beginning to act far more decisively and stay far more vigilant about it. So my expectation would be that they'd behave the same way with nicotine pouches. In short, I don't believe we're witnessing anything significant today that shouldn't definitely be watched; and if that were to change, we'd anticipate the same sort of proactive stance from the authorities that they — as I see it — are starting to put into practice regarding vaping.
Callum Elliott
analystSo this is a follow-up, and honestly it's fairly close to what you were just asked a moment ago, but I'd like to take it a step or two further, since, just like Owen, we're now seeing fairly broad evidence that European moist versions of ZYN — which, as far as I understand, don't hold premarket approval and weren't on the market as of August 2016 — are being offered for sale on a fairly wide basis throughout New York City; and beyond that, what we see online indicates this has turned into a fairly extensive problem throughout the entire U.S.; so I suppose that's 2 questions. Could you simply verify for us that those products weren't available in the market of August 2016 and that selling them violates FDA regulations? And then, secondly, I suppose, picking up on Owen's question, assuming you aren't yourselves selling a list of product straight to U.S. retailers — so what options do you have? And what steps are you taking to prevent European e-commerce retailers from selling this product? Because it seems to me this creates a fairly significant potential risk to your U.S. ZYN business if this illicit product keeps coming into the U.S. market this way.
Emmanuel Babeau
executiveThanks, Callum. Look, once again, I have no data regarding what you're describing. So reporting on it is very difficult for me. I believe we're aware of whether the product that gains from the situation and the positioning in 2016 in the market and that, as a result, is legally being commercialized. . As you can imagine, I'll simply say again what I've already said. We're making every effort to control the flows. I have no information today indicating that you have these flows of product. If we did know, we would definitely address that, and we would attempt to figure out where it originates; and what I can definitely say again is that our goal is to do our utmost, everything we can, to remain compliant with the regulation. And truly, there's nothing further I can add.
Callum Elliott
analystAll right. Perhaps a quick follow-up as well. I suppose, when you consider restoring supply in the U.S. while also adding fresh supply to satisfy demand, why are you so confident that we will witness that kind of upward boost in today's ZYN guidance? It suggests quite a substantial second-half hockey stick when it comes to a positive inflection in the growth rate. And, regarding Faham's earlier question, quarter-to-date we are seeing sequential declines in growth. So why do you have the confidence that consumers are moving to — consumers who are moving to Rogue, a few of the consumer reviews for some of these rival products are at times superior to this. So why are you confident that, now that consumer awareness of these other brands has increased because of your supply chain problems, you will instantly regain those consumers once supply returns?
Emmanuel Babeau
executiveLook, Callum, this clearly stems from a combination of the consumer demand perception that we hold; and we think that if we are able to produce them, there is room to reach 580 million can shipments. That is the first component. And that is what our senses indicate to us, what a consumer would gladly purchase if it were on offer. And simultaneously, naturally, our steps to boost production capacity, where, as I mentioned, I will not go into detail on the different levers, yet we are pulling several levers to steadily raise capacity for ZYN production in the U.S. So that is truly the blend of the 2.
Priya Ohri-Gupta
analystEmmanuel, I'd like to ask whether you might share a bit more detail regarding the IQOS ILUMA trials you have in the works for the United States; from what I gather, it's only a handful of cities. Are those going to be spread out in different regions geographically throughout America? And which insights are you expecting to, I believe, gain from them? Also, in what ways might this differ from what we witnessed at the outset a number of years back with certain of those stand-alone shops that got established? Then I've got one more question after that.
Emmanuel Babeau
executiveOf course, Priya. That's quite a wide-ranging inquiry, though certainly a significant one; so considering our situation, I'll keep my response brief on this. To begin with, let's make clear that a broad rollout happens only after we secure the PMTA for ILUMA. As I mentioned during my opening comments, our current aim remains obtaining that clearance during the latter portion of 2025. After that point arrives, we'll possess the proper offering to expand much more widely across America. And by then, we'll have gained knowledge from various initiatives we intend to carry out from Q4 until the time we introduce ILUMA; and — you're asking, right, what will you approach differently? Let's — let's be straightforward, we don't think IQOS has ever been introduced in any truly serious, steady and deep fashion; and we think that whatever has made IQOS so favored beyond America will connect with many smokers among the roughly 30 million smokers in America. So we're going to build upon what has succeeded in other places. It'll involve, naturally, reaching out to smokers to describe what IQOS represents, to describe the experience, to explain why IQOS beats smoking as a product. I believe it will be, as ever, extremely crucial to establish the perception, the brand identity, while also engaging in close dialogue with smokers, alright, this is a path toward leaving smoking behind and adopting a superior alternative in IQOS. We'll deploy the identical commercial, let's say, apparatus that has proven effective across so many markets by building our own points of sale; we'll maintain a robust collaboration with numerous independent as well as third-party merchants. So we intend to utilize every available tool, something that hasn't occurred in America. Since up to this point, there's been merely a quite restricted introduction across a small number of cities with minimal activity; so everything will kick off at that time for IQOS and there's no magic involved; we'll apply whatever has performed so effectively in other regions, naturally tailoring it for the American market.
Priya Ohri-Gupta
analystThat's quite useful. And I suppose, as something that builds on it, you spent a lot of time discussing how IQOS and VEEV have grown outside the U.S. Perhaps in general terms, how might that product unfold in the U.S.? And when would you consider submitting PMTAs and afterward expanding its availability in the U.S.?
Emmanuel Babeau
executiveWell, as things stand right now, we have no intention of submitting a PMTA for these. Our focus is heavily on IQOS. I'd say this achievement is only starting as of today. Having 5 markets already where we hold the #1 spot in the closed pods system is wonderful, yet that's merely the start. We'll continue to learn and to figure out how to build a successful, profitable vaping business. After that, we'll see if at some appropriate time it could be worth considering something like this for the U.S., though today we haven't reached that point.
Priya Ohri-Gupta
analystOne last thing, I believe, on the administrative side. You mentioned that interest expense sits at the bottom of the earlier guidance, $1.3 billion. Is that, I suppose, a reflection of the issuance completed so far? And ought we to expect no further interest expense pressure, meaning there could be room for additional refinancing or prefinancing you might look at?
Emmanuel Babeau
executiveNo. The better projected financial cost for the year, I believe, mirrors an improved position regarding, first, the debt level alongside cash flow generation. Second, the manner in which we finance the group. And that comes with this — as you put it, we sit at the bottom of the original bracket. Nor should any sort of revolution in how the company is financed be anticipated, with nothing on the agenda.
James Bushnell
executiveThat wraps up the session for today. We appreciate everyone for being with us. Should any further questions come up, you can reach out to the PMI Investor Relations team. Thanks once more, and enjoy the rest of your day.
Emmanuel Babeau
executiveThank you.
Operator
operatorThis concludes today's conference call. Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.